Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00437671 · ClinicalTrials.gov registry record · Phase 4
Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels
A Phase 4 study, sponsored by Grifols Therapeutics.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT00437671 is a Phase 4 study that was terminated before completion, run by Grifols Therapeutics. The registered enrollment target is 6 participants.
The verdict
NCT00437671, a Phase 4 study, was terminated before completion, sponsored by Grifols Therapeutics.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
The goal of this study is to re-evaluate the tetanus antibody pharmacokinetic profile when Tetanus Immune Globulin (Human)(TIG) and Tetanus vaccine (Tetanus toxoid; TT) are given concurrently with strict control on the anatomical location and timing of administration of TIG and TT. Pharmacokinetic profile of antibody titer including the duration of adequate titer protection provided by TIG and TT given in combination will be assessed using a standardized administration regimen and standardized antibody assay procedure. This study may provide evidence for the recommendations of the World Health Organisation (WHO) whereby dual coverage with both a vaccine and tetanus hyperimmune would ideally provide the best coverage for anyone with the potential of developing tetanus.
Interventions
- DRUG Tetanus Immune Globulin (Human)
- BIOLOGICAL Diphtheria-Tetanus Toxoids Adsorbed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-03 |
| Est. Completion | 2007-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00437671
The ClinicalTrials.gov registry entry for NCT00437671 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Grifols Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tetanus Immune Globulin (Human) is the first listed.
NCT00437671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00437671 about?
NCT00437671 is a clinical study titled "Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels". The goal of this study is to re-evaluate the tetanus antibody pharmacokinetic profile when Tetanus Immune Globulin (Human)(TIG) and Tetanus vaccine (Tetanus toxoid; TT) are given concurrently with strict control on the anatomical location and timing of administration of TIG and TT. Pharmacokinetic p...
What is the current status of trial NCT00437671?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2007-03. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00437671?
The interventions under investigation include: Tetanus Immune Globulin (Human) (DRUG), Diphtheria-Tetanus Toxoids Adsorbed (BIOLOGICAL).
Who is sponsoring clinical trial NCT00437671?
This trial is sponsored by Grifols Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.